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MICAbstract In continuation of our research on nitrogen containing heterocyclic compounds to
develop potent antimicrobial and antimycobacterial agents, some novel 2(3H) pyrrolone derivatives
were synthesized. We report here two new series of 3-Arylidene-5-(4-chloro/methyl phenyl)-2(3H)
pyrrolones (14–19) and 3-Arylidene-5-(4-chloro/methyl phenyl)-1-benzyl-2(3H) pyrrolones
(20–25) prepared by reacting intermediate furanone compounds (6–13) with ammonia gas and
benzylamine respectively. The structures of the title compounds were established on the basis of
IR, 1H NMR, mass spectral data and elemental analysis results. All the synthesized pyrrolone deriv-
atives were evaluated for their possible antibacterial, antifungal and antitubercular activities.
Among all the synthesized compounds, compound 17, 3-(4-Hydroxy-3-methoxybenzylidene)-5-
(4-chlorophenyl)-2(3H)-pyrrolone, emerged as a lead compound exhibiting the highest
antibacterial, antifungal and antitubercular activity against Staphylococcus aureus, Escherichia coli,
Pseudomonas aeruginosa and Mycobacterium tuberculosis with 6.25 lg/mL MIC (minimum
Antimicrobial activities of novel 2(3H) pyrrolone derivatives 341inhibitory concentration). Molecular properties of pyrrolones were also calculated by Molinspira-
tion software for drug likeness. It was observed that all 2(3H) pyrrolones (14–19) obeyed Lippin-
ski’s rule of ﬁve and expected to be orally active. They were also found to be more potent
antimicrobial agents than 1-benzyl-2(3H) pyrrolones (20–25) and their activity was comparable
with standard drugs such as Ciproﬂoxacin, Ketoconazole and Streptomycin.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Discovery of penicillin by Alexander Fleming in 1928 was a
vital breakthrough against systemic bacterial infections and
since then a number of antimicrobial agents have been devel-
oped. These agents have been used with great success against
the life threatening diseases but in recent times microbial infec-
tions, particularly of nosocomial origin, are on the rise due to
suppression of immunity as a result of old age, malignancy,
immunosuppressive therapies, steroids, surgeries etc. [1,2].
This has led to indiscriminate and over use of antimicrobials
against the pathogens to control minor as well as major infec-
tions. Widespread use, irrational prescribing or misuse of anti-
biotics have partly contributed to the emergence of resistant
bacterial strains, a serious problem worldwide [3]. If antibiotic
resistance continues to grow in the same fashion, we could
have scarcity of medicines to treat the infections. To overcome
this problem of microbial resistance, new and improved anti-
microbials acting on multi targets need to be developed.
The chemistry of ﬁve membered nitrogen containing
heterocyclic compounds such as pyrrolones has attracted more
attention during recent years due to their reactivity and
interesting pharmacological activities. Pyrrolones are also
present in natural products viz. prodigiosin, bilepigments,
and some antibiotics like distamycin [4,5]. Pyrrolone deriva-
tives have been reported to possess numerous biological activ-
ities. They act as inhibitor of cardiac cAMP phosphodiesterase
[6], exhibit anticonvulsant activity [7], immunosuppressive
activity [8], analgesic and anti-inﬂammatory activity [9], anti-
cancer activity [10], antibacterial and antifungal activities [11]
etc. Considering the above pharmacological activities of this
heterocyclic moiety, we have synthesized some novel 2(3H)-
pyrrolone derivatives and evaluated them for the anticipated
antibacterial, antifungal and antitubercular activities in the
hope of developing pharmaceutically important antimicrobial
agents.
2. Results and discussion
2.1. Chemistry
The title compounds bearing the pyrrolone ring were
synthesized as outlined in Scheme 1. 2(3H) furanones, the
key intermediate in the synthesis of pyrrolones were prepared
according to modiﬁed Perkin’s reaction by reacting
3-(4-chloro/methylbenzoyl)propionic acid (4, 5) with different
aromatic aldehydes in good yields [12]. 3-Arylidene-5-(4-
chloro/methyl phenyl)-2(3H)-pyrrolones (14–19) and 3-arylid-
ene-5-(4-chloro/methyl phenyl)-1-benzyl-2(3H)-pyrrolones
(20–25) were synthesized by reacting appropriate furanones
(6–13) with ammonia gas in absolute ethanol and benzylaminein dry benzene followed by lactamization with 6 M HCl
respectively (Table 1). The structures assigned to the desired
pyrrolones were supported by IR, 1H NMR, mass spectral
data and elemental analysis results.
The IR spectra of 2(3H) pyrrolones showed absorption
bands (cm1) at 3412–3465 (–NH); 3108–3142 (CAH) and
1693–1706 (C‚O). Infrared spectral data of benzyl pyrrolones
also revealed bands around 3050 (CAH), 1725 (C‚O) and
1600 (CAN). 1H NMR spectral data of 14–19 exhibited a sin-
glet around d 6.4 which could be assigned to the lone proton of
the pyrrolone ring. There appeared another singlet around d
7.3 integrating for the oleﬁnic hydrogen of the arylidene substi-
tuent. 1H NMR spectral data of 20–25 showed a singlet
around d 4.8 which could be accounted for methylene protons
(ACH2A) of N-benzyl moiety. There appeared two more sing-
lets each around d 6.2 and d 7.5 integrating for the lone proton
of the pyrrolone ring and the oleﬁnic hydrogen, respectively.
Other signals were observed at appropriate d values integrating
for the protons of two phenyl rings and three phenyl rings for
pyrrolone and benzyl pyrrolones respectively. Mass spectra of
all pyrrolone analogs showed the presence of molecular ion
peaks (M+) in reasonable intensities. The molecular ion peak
or its fragments having chloro-substituent(s) appeared as a
cluster of peaks. Elemental analyses (CHN) were also found
within the range of ±0.4% of theoretical values.2.2. Molecular properties
Oral bioavailability is considered as an important parameter
for the development of highly effective therapeutic agents.
Molecular properties such as partition coefﬁcient (log P),
molecular weight, polar surface area, number of rotatable
bonds, counts of hydrogen bond acceptors and donors in the
molecule etc. are often used to predict bioavailability or mem-
brane permeability [13]. Lipinski’s rule is widely used to deter-
mine molecular properties that are important for drug’s
pharmacokinetic in vivo [14]. It is used as a ﬁlter for drug like
properties and helps pharmaceutical scientists to select the best
candidates for the development with a high probability of
success.
According to Lipinski’s ‘‘rule of ﬁve’’, a candidate molecule
is more likely to have good membrane permeability i.e. orally
active, if: (a) the molecular weight is 6 500, (b) the calculated
octanol/water partition coefﬁcient (log P) is 65, (c) there are
not more than 5 hydrogen bond donors (OH and NH groups),
(d) there are not more than 10 hydrogen bond acceptors (nota-
bly N and O) [14]. The molecular properties of investigated
compounds (14–25) were computed by using freely accessible
online Molinspiration cheminformatics software [15] and are
presented in Table 2. No violation of Lipinski’s rule of ﬁve
was observed in case of compounds (14–19), however benzyl
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Scheme 1 Protocol for the synthesis of pyrrolones.
Table 1 Physical properties of synthesized compounds (14–25).
X
O
R1
R
Compound code R X R1 Molecular formula m.p. (C) Rf value % Yield
14 –Cl NH 4-OH C17H12ClNO2 181 0.78 71
15 –Cl –NH 2-OH C17H12ClNO2 166 0.73 74
16 –Cl –NH 4-CH3 C18H14ClNO 178 0.68 67
17 –Cl –NH 4-OH, 3-OCH3 C18H14ClNO3 136 0.75 64
18 –Cl –NH 3,4 (–OCH3)2 C19H16ClNO3 158 0.72 62
19 –CH3 –NH 4-OH, 3-OCH3 C19H17NO3 160 0.71 62
20 –Cl –NCH2–Ph 4-OH C24H18ClNO2 201 0.72 56
21 –Cl –NCH2–Ph 2-OH C24H18ClNO2 169 0.70 54
22 –Cl –NCH2–Ph 4-CH3 C25H20ClNO 160 0.73 50
23 –Cl –NCH2–Ph 3,4 (–OCH3)2 C26H22ClNO3 152 0.71 52
24 –CH3 –NCH2–Ph 4-OH, 3-OCH3 C26H23NO3 158 0.72 52
25 –CH3 –NCH2-Ph 4-OCH3 C26H23NO2 153 0.71 54
342 A. Ahmad et al.pyrrolone derivatives showed one violation barring compound
number 24. Thus on the basis of these results it can be
concluded that 2(3H) pyrrolones are more likely to be orally
active as therapeutic agents in comparison to 2(3H) benzyl
pyrrolones.2.3. Antimicrobial evaluation
2.3.1. Antibacterial activity
Synthesized compounds were tested for antibacterial activity
against one gram positive organism (Staphylococcus aureus)
Table 2 Molecular properties of pyrrolone derivatives calculated by Molinspiration cheminformatics software.
Compd. No. miLog Pa TPSAb nAtoms nONc nOHNHd n violation n rotb.e Volume MWf
14 3.696 53.09 21 3 2 0 2 252.383 297.741
15 4.115 53.09 21 3 2 0 2 252.383 297.741
16 4.624 32.86 21 2 1 0 2 260.927 295.769
17 3.514 62.32 23 4 2 0 3 277.929 327.767
18 3.822 51.33 24 4 1 0 4 295.457 341.794
19 3.285 62.32 23 4 2 0 3 280.954 307.349
20 5.358 42.23 28 3 1 1 4 340.975 387.866
21 5.778 42.23 28 3 1 1 4 340.975 387.866
22 6.286 22.00 28 2 0 1 4 349.518 385.894
23 5.484 40.47 31 4 0 1 6 384.049 431.919
24 4.947 51.46 30 4 1 0 5 369.546 397.474
25 5.665 31.23 29 3 0 1 5 361.528 381.475
a Partition coefﬁcient.
b Total polar surface area.
c Number of hydrogen bond acceptor.
d Number of hydrogen bond donors.
e Number of rotatable bonds.
f Molecular weight.
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Pseudomonas aeruginosa). The results of antibacterial activity
indicated signiﬁcant inhibitory activity and majority of the
compounds showed MIC in the range of 6.25–50 lg/mL. The
most potent antibacterial compound was found to be
3-(4-Hydroxy-3-methoxybenzylidene)-5-(4-chlorophenyl)-2(3H)-
pyrrolone (Compd. 17) with MIC-6.25 lg/mL. The MIC of
this compound 17 was found to be at par with that of the
standard drug Ciproﬂoxacin. However, 3-(2-Hydroxybenzy-
lidene)-5-(4-chlorophenyl)-2(3H)-pyrrolone 15, 3-(4-Hydrox-
ybenzylidene)-5-(4-chlorophenyl)-1-benzyl-2(3H)-pyrrolone 20
and 3-(4-Methoxybenzylidene)-5-(4-methylphenyl)-1-benzyl-
2(3H)-pyrrolone 25 showed very poor inhibitory activity
(MIC> 100 lg/mL). A result of antibacterial activity of
compounds is shown in Table 3.
2.3.2. Antifungal activity
The antifungal activities of the pyrrolone analogs were evalu-
ated against Candida albicans and Aspergillus niger fungalTable 3 Antimicrobial activity (MIC; lg/mL) of pyrrolones (14–19
Compd. No. Antibacterial activity
S. aureus E. coli P. aeruginosa
14 50 50 50
15 >100 50 >100
16 25 25 50
17 6.25 6.25 6.25
18 12.5 12.5 6.25
19 25 25 50
20 >100 50 >100
21 50 25 50
22 25 50 >100
23 25 25 50
25 >100 >100 >100
24 25 25 25
Ciproﬂoxacin 6.25 6.25 6.25
Ketoconazole nt nt nt
Streptomycin nt nt nt
nt: not tested; MIC: minimum inhibitory concentration.organisms. Two of the tested compounds 3-(4-Hydroxy-3-
methoxybenzylidene)-5-(4-chlorophenyl)-2(3H)-pyrrolone 17
and 3-(4-Hydroxy-3-methoxybenzylidene)-5-(4-methyl-
phenyl)-2(3H)-pyrrolone 19 were found to be the most potent
antifungal agents. Compound 17 showed signiﬁcant inhibitory
against A. niger (MIC 6.25 lg/mL) while compound 19 was
more potent against C. albicans (MIC; 6.25 lg/mL). The anti-
fungal activity of these compounds was comparable with the
reference drug Ketoconazole. Compound number 15 and 25
did not exhibit any signiﬁcant activity (MIC > 100 lg/mL).
Rest of the compounds demonstrated moderate antifungal
activity (MIC; 25–50 lg/mL). Antifungal activity of the
compounds 14–25 is summarized in Table 3.
2.3.3. Antitubercular activity
The antitubercular screening was carried out againstMycobac-
terium tuberculosisH37Rv (ATCC-27294) (Table 3). The results
showed that 3-(4-Hydroxy-3-methoxybenzylidene)-5-(4-chlo-
rophenyl)-2(3H)-pyrrolone 17 exhibited best antitubercular) and N-benzyl pyrrolones (20–25).
Antifungal activity Antitubercular activity
C. albicans A. niger M. tuberculosis
>100 50 12.5
>100 >100 50
50 50 25
12.5 6.25 6.25
25 25 12.5
6.25 12.5 12.5
50 >100 50
25 50 50
50 >100 25
>100 50 >100
>100 >100 >100
50 25 25
nt nt Nt
6.25 6.25 Nt
nt nt 6.25
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mL and was similar to standard drug Streptomycin. Three
compounds namely; 3-(4-Hydroxybenzylidene)-5-(4-chloro-
phenyl)-2(3H)-pyrrolone 14, 3-(3,4-Dimethoxybenzylidene)-
5-(4-chlorophenyl)-2(3H)-pyrrolone 18 and 3-(4-Hydroxy-3-
methoxybenzylidene)-5-(4-methylphenyl)-2(3H)-pyrrolone 19
were also signiﬁcant in their antitubercular action with MIC
of 12.5 lg/mL. Rest of the compounds (except 23 and 25)
showed moderate activity (MIC; 25–50 lg/mL).
3. Experimental section
3.1. General
All the reagents and solvents were of LR grade and were
obtained from Merck (Mumbai, India), CDH (New Delhi,
India) and S.D. ﬁne (Mumbai, India). Melting points were
recorded in a liquid parafﬁn bath using open end capillaries
and are uncorrected. The IR spectra (in KBr pellets) were
recorded on a Thermo Nicolet avatar 330-FT-IR spectropho-
tometer. 1H NMR spectra were recorded on Bruker spectro-
spin DPX-300 MHz in CDCl3; chemical shift (d) values are
reported in parts per million (ppm). The splitting pattern
abbreviations are as follows: s, singlet; d, doublet; dd, double
doublet; m, multiplet. Mass spectroscopic analyses for com-
pounds were performed on a JEOL JMS-D 300 instrument.
Elemental analyses were performed on a Perkin-Elmer 240
analyzer and were in the range of ±0.4% for each element
analyzed (C, H, N). Molecular properties such as log P, Total
polar surface area, number of hydrogen bond donors and
acceptors, molecular weight, number of atoms, number of
rotatable bonds etc. were calculated by using an online Molin-
spiration software version 2011.06 (www.molinspiration.com).
Thin-layer chromatography (TLC) was done to monitor the
progress of reactions using silica gel G (Merck) as stationary
phase in the solvent system-toluene:ethyl acetate:formic acid
(5:4:1, v/v/v); iodine chamber, and UV lamp was used for visu-
alization of TLC spots. The protocol for the synthesis leading
to the title compounds is summarized in Scheme 1.
3.2. Synthesis of the compounds
3.2.1. Synthesis of 3-(4-chloro/methyl benzoyl)propionic acid
(4, 5)
These were prepared by condensing chlorobenzene (1) and
toluene (2) with succinic anhydride (3) in the presence of anhy-
drous aluminum chloride as per the reported method [11].
3.2.2. Synthesis of 3-arylidene-5-(4-chloro/methyl phenyl)-
2(3H)furanones (6–13)
Compounds (6–13) were synthesized by condensing 3-(4-
chloro/methyl benozyl) propionic acid (4, 5) with substituted
aromatic aldehydes as previously reported [16].
3.2.3. General procedure for the synthesis of 3-arylidene-5-
(4-chloro/methyl phenyl)-2(3H)-pyrrolones (14–19)
Dry ammonia gas was passed over the anhydrous ethanolic
solution of various 2(3H)-furanones (3 mmol) for 1 h at room
temperature, ethanol was distilled off under reduced pressure
and the solid mass so obtained was crystallized from metha-
nol/acetone to furnish TLC pure compounds.3.2.3.1. 3-(4-Hydroxybenzylidene)-5-(4-chlorophenyl)-2(3H)-
pyrrolone (14). IR (KBr, cm1): 3461 (–NH), 3314 (–OH),
3142 (CAH), 1706 (C‚O), 711 (CACl). 1H NMR (CDCl3,
d, ppm): 6.47 (s, 1H, pyrrolone ring), 7.36 (s, 1H, oleﬁnic
H), 7.38 and 7.58 (d, each, A2B2, p-hydroxyphenyl ring),
7.49 and 7.66 (d, each, A2B2, p-chloro-phenyl ring). Anal
calcd. for C17H12ClNO2: C, 68.58; H, 4.06; N, 4.70; Found:
C, 68.36; H, 4.21; N, 4.64. MS (ESI, m/z): 297 (M+).
3.2.3.2. 3-(2-Hydroxybenzylidene)-5-(4-chlorophenyl)-2(3H)-
pyrrolone (15). IR (KBr, cm1): 3455 (–NH), 3308 (–OH),
3140 (CAH), 1702 (C‚O), 709 (CACl). 1H NMR (CDCl3,
d, ppm): 6.51 (s, 1H, pyrrolone ring), 7.34 (s, 1H, oleﬁnic
H), 7.41–7.64 (m, 4H, o-hydroxyphenyl ring), 7.47 and 7.67
(d, each, A2B2, p-chloro-phenyl ring). Anal calcd. for C17H12-
ClNO2: C, 68.58; H, 4.06; N, 4.70; Found: C, 68.43; H, 3.95;
N, 4.78. MS (ESI, m/z): 297 (M+).
3.2.3.3. 3-(4-Methylbenzylidene)-5-(4-chlorophenyl)-2(3H)-
pyrrolone (16). IR (KBr, cm1): 3463 (–NH), 3141 (–CH),
1693 (C‚O), 706 (CACl). 1H NMR (CDCl3, d, ppm): 2.35
(s, 3H, CH3), 6.54 (s, 1H, pyrrolone ring), 7.35 and 7.63 (d,
each, A2B2, p-tolyl ring), 7.40 (s, 1H, oleﬁnic H), 7.45 and
7.52 (d, each, A2B2, p-chloro-phenyl ring). Anal calcd. for C18-
H14ClNO: C, 73.10; H, 4.77; N, 4.74; Found: C, 72.86; H, 4.65;
N, 4.82. MS (ESI, m/z): 295 (M+).
3.2.3.4. 3-(4-Hydroxy-3-methoxybenzylidene)-5-(4-chloro-
phenyl)-2(3H)-pyrrolone (17). IR (KBr, cm1): 3465 (–NH),
3232 (–OH), 3145 (CAH), 1699 (C‚O), 681 (CACl). 1H
NMR (CDCl3, d, ppm): 3.75 (s, 3H, OCH3), 6.50 (s, 1H, pyr-
rolone ring), 7.40–7.71 (m, 8H, p-chlorophenyl ring + arylid-
ene ring + oleﬁnic H). Anal calcd. for C18H14ClNO3: C,
65.96; H, 4.31; N, 4.27; Found: C, 65.83; H, 4.28; N, 4.23.
MS (ESI, m/z): 327 (M+).
3.2.3.5. 3-(3,4-Dimethoxybenzylidene)-5-(4-chlorophenyl)-
2(3H)-pyrrolone (18). IR (KBr, cm1): 3412 (–NH), 3108
(CAH), 1695 (C‚O), 699 (CACl). 1H NMR (CDCl3, d,
ppm): 3.93 (s, 6H, 2xOCH3), 6.48 (s, 1H, pyrrolone ring),
6.96 (d, 1H, H-5, arylidene ring), 7.14 (s, 1H, H-2, arylidene
ring), 7.31 (d, 1H, H-6, arylidene ring), 7.39 (s, 1H, oleﬁnic
H), 7.45 and 7.63 (d, each, A2B2, p-chloro-phenyl ring). Anal
calcd. for C19H16ClNO3: C, 66.77; H, 4.72; N, 4.10; Found:
C, 66.45; H, 4.60; N, 3.88. MS (ESI, m/z): 341 (M+).
3.2.3.6. 3-(4-Hydroxy-3-methoxybenzylidene)-5-(4-methyl-
phenyl)-2(3H)-pyrrolone (19). IR (KBr, cm1): 3421 (–NH),
3233 (–OH), 3116 (CAH), 1695 (C‚O). 1H-NMR (CDCl3,
d, ppm): 2.21 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 6.53 (s, 1H,
pyrrolone ring), 7.03 (d, 1H, H-5, arylidene ring), 7.11 and
7.27 (d, each, A2B2, p-tolyl ring), 7.17 (s, 1H, H-2, arylidene
ring), 7.33 (s, 1H, oleﬁnic H), 7.38 (d, 1H, H-6, arylidene ring).
Anal calcd. for C19H17NO3:C, 74.25; H, 5.58; N, 4.56; Found:
C, 74.10; H, 5.45; N, 4.42. MS (ESI, m/z): 307 (M+).
3.2.4. General procedure for the synthesis of 3-arylidene-5-(4-
chloro/methyl phenyl)-1-benzyl-2(3H)-pyrrolones (20–25)
The syntheses of these compounds were accomplished in
two steps. In the ﬁrst step c-ketobenzylamide was synthesized
by reﬂuxing appropriate 2(3H)-furanone (3 mmol) and
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of reaction, an excess of benzene was distilled off and a solid
mass so obtained was washed with petroleum ether and dried.
The compound obtained was used without crystallization. In
the second step, desired pyrrolones (20–25) were obtained by
lactamization of c-ketobenzylamide (3 mmol) by reﬂuxing in
6 M hydrochloric acid (20 mL) for 1 h. The contents were then
cooled and a solid mass so obtained was collected, washed
with water and crystallized from methanol to yield the TLC
pure compounds.
3.2.4.1. 3-(4-Hydroxybenzylidene)-5-(4-chlorophenyl)-1-ben-
zyl-2(3H)-pyrrolone (20). IR (KBr, cm1): 3236 (–OH),
3035 (CAH), 1724 (C‚O), 1610 (CAN), 784 (CACl). 1H
NMR (CDCl3, d, ppm): 4.82 (s, CH2), 6.26 (s, 1H, pyrrolone
ring), 7.23 and 7.44 (d, each, A2B2, p-chlorophenyl ring),
7.28–7.36 (m, 5H, benzyl), 7.39 and 7.81 (d, each, A2B2,
p-hydroxyphenyl ring), 7.50 (s, 1H, oleﬁnic H). Anal calcd.
for C24H18ClNO2: C, 74.32; H, 4.68; N, 3.61; Found: C,
74.18; H, 4.65; N, 3.63. MS (ESI, m/z): 387 (M+).
3.2.4.2. 3-(2-Hydroxybenzylidene)-5-(4-chlorophenyl)-1-ben-
zyl-2(3H)-pyrrolone (21). IR (KBr, cm1): 3241 (–OH),
3042 (CAH), 1727 (C‚O), 1616 (CAN), 781 (CACl). 1H
NMR (CDCl3, d, ppm): 4.85 (s, CH2), 6.18 (s, 1H, pyrrolone
ring), 7.21 and 7.46 (d, each, A2B2, p-chlorophenyl ring),
7.26–7.35 (m, 5H, benzyl), 7.38–7.83 (m, 5H, o-hydroxyphenyl
ring + oleﬁnic H). Anal calcd. for C24H18ClNO2: C, 74.32; H,
4.68; N, 3.61; Found: C, 74.18; H, 4.65; N, 3.63. MS (ESI, m/
z): 387 (M+).
3.2.4.3. 3-(4-Methylbenzylidene)-5-(4-chlorophenyl)-1-benzyl-
2(3H)-pyrrolone (22). IR (KBr, cm1): 3046 (CAH), 1732
(C‚O), 1617 (CAN), 745 (CACl). 1H NMR (CDCl3, d,
ppm): 2.33 (s, 3H, CH3), 4.84 (s, CH2), 6.09 (s, 1H, pyrrolone
ring), 7.08–7.82 (m, 14H, p-tolyl ring + benzyl + p-chloro-
phenyl ring + oleﬁnic H). Anal calcd. for C25H20ClNO: C,
77.81; H, 5.22; N, 3.63; Found: C, 77.38; H, 5.06; N, 3.55.
MS (ESI, m/z): 385 (M+).
3.2.4.4. 3-(3,4-Dimethoxybenzylidene)-5-(4-chlorophenyl)-1-
benzyl-2(3H)-pyrrolone (23). IR (KBr, cm1): 3033 (CAH),
1728 (C‚O), 1608 (CAN), 735 (CACl). 1H NMR (CDCl3, d,
ppm): 3.93 (s, 6H, 2xOCH3), 4.84 (s, CH2), 6.22 (s, 1H, pyrro-
lone ring), 7.18–7.31 (m, 5H, benzyl), 7.33 and 7.59 (d, each,
A2B2, p-chlorophenyl ring), 7.36–7.41 (m, 1H, H-5, arylidene
ring), 7.48 (s, 1H, oleﬁnic H), 7.56–7.68 (m, 2H,H-2,6, arylidene
ring). Anal calcd. for C26H22ClNO3: C, 72.30; H, 5.13; N, 3.24;
Found: C, 72.12; H, 5.28; N, 3.12. MS (ESI, m/z): 431 (M+).
3.2.4.5. 3-(4-Hydroxy-3-methoxybenzylidene)-5-(4-methyl-
phenyl)-1-benzyl-2(3H)-pyrrolone (24). IR (KBr, cm1):
3316 (–OH), 2908 (CAH), 1738 (C‚O), 1608 (CAN). 1H
NMR (CDCl3, d, ppm): 2.34 (s, 3H, CH3), 3.69 (s, 3H,
OCH3), 4.85 (s, 2H, CH2), 6.80 (s, 1H, pyrrolone ring), 7.18–
7.87 (complex m, 13H, p-tolyl ring + benzyl ring + arylidene
ring + oleﬁnic H). Anal calcd. for C26H23NO3: C, 78.57; H,
5.83; N, 3.52; Found: C, 78.38; H, 5.72; N, 3.41. MS (ESI,
m/z): 397 (M+).
3.2.4.6. 3-(4-Methoxybenzylidene)-5-(4-methylphenyl)-1-ben-
zyl-2(3H)-pyrrolone (25). IR (KBr, cm1): 3051 (CAH),1726 (C‚O), 1614 (CAN). 1H NMR (CDCl3, d, ppm): 2.34
(s, 3H, CH3), 3.83 (s, 3H, OCH3), 4.85 (s, CH2), 6.21 (s, 1H,
pyrrolone ring), 7.09 and 7.56 (d, each, A2B2, p-tolyl ring),
7.15 and 7.48 (d, each, A2B2, arylidene ring), 7.22–7.37 (m,
5H, benzyl), 7.54 (s, 1H, oleﬁnic H). Anal calcd. for
C26H23NO2: C, 81.86; H, 6.08; N, 3.67; Found: C, 81.77; H,
6.21; N, 3.50. MS (ESI, m/z): 381 (M+).
3.3. Antimicrobial studies
3.3.1. Antibacterial activity
All synthesized 2(3H)-pyrrolone compounds were screened
against three bacterial strains viz. S. aureus (ATCC-25923),
E. coli (ATCC-25922) and P. aeruginosa (ATCC-27853) and
minimum inhibitory concentration (MIC) was determined by
the broth dilution technique [17]. A standard drug (Ciproﬂox-
acin) was used for comparison of the antibacterial activity.
3.3.2. Antifungal activity
Antifungal activity of the title compounds was determined
against C. albicans (ATCC-10231) and A. niger (ATCC-
16404) by the agar diffusion method [18]. Ketoconazole was
used as standard drug for comparison.
3.3.3. Antitubercular activity
The antitubercular activity of the synthesized compounds was
evaluated againstM. tuberculosis H37Rv (ATCC-27294) by the
agar microdilution method where twofold dilutions of each
test compound were added into 7H11 agar medium supple-
mented with OADC (oleic acid albumin dextrose catalase)
and organism [19,20]. Streptomycin was used as a reference
drug for comparison.
4. Conclusion
The results of the present study are quite encouraging and the
synthesized compounds are potential candidates for further
studies. Pyrrolone derivatives (14–25) were obtained in good
yield and exhibited quite signiﬁcant antimicrobial activities. 3-
(4-Hydroxy-3-methoxybenzylidene)-5-(4-chlorophenyl)-2(3H)-
pyrrolone (Compd No. 17), emerged as a lead compound
exhibiting the highest antibacterial, antifungal and
antitubercular activity against S. aureus, E. coli, P. aeruginosa
and M. tuberculosis with 6.25 lg/mL MIC and its activity was
comparable with that of the standard drugs. However,
pyrrolones were slightly better than benzyl-pyrrolones in their
antimicrobial potential. Further studies are needed to study
their mechanism of action and toxicological proﬁle to develop
potent antimicrobial agents.References
[1] K.D. Olczak, M. Daszkiewicz, K. Slawinska, D.B. Baginska, D.
Gozdowski, P. Daszkiewicz, B. Fronc, K. Semczuk, Bacteria
and Candida yeasts in inﬂammations of the oral mucosa in
children with secondary immunodeﬁciency, J. Oral. Pathol.
Med. 41 (2012) 568–576.
[2] D.M. Livermore, M. Warner, S. Mushtaq, M. Doumith, J.
Zhang, N. Woodford, What remains against
carbapenemresistant enterobacteriaceae? Evaluation of
chloramphenicol, ciproﬂoxacin, colistin, fosfomycin,
346 A. Ahmad et al.minocycline, nitrofurantoin, temocillin and tigecycline, Int. J.
Antimicrob. Agents 37 (2011) 415–419.
[3] M. Danishuddin, L. Kaushal, M.H. Baig, A.U. Khan, AMDD:
antimicrobial drug database, Genomics Proteomics
Bioinformatics 10 (2012) 360–363.
[4] W.J. Koot, H. Hiemstra, W.N. Speckamp, (R)-1-Acetyl-5-
isopropoxy-3-pyrrolin-2-one: a versatile chiral dienophile from
(S)-malic acid, J. Org. Chem. 57 (1992) 1059–1061.
[5] G.R. Birchall, C.G. Hughes, A.H. Rees, Newer syntheses of the
pyoluteorin antibiotics, Tetrahedron Lett. 56 (1970) 4879–4882.
[6] J.W. Lampe, Y.L. Chou, R.G. Hanna, S.V. Di Meo, P.W.
Erhardt, A.A. Hagedorn, W.R. Ingebretsen, E. Cantor,
(Imidazolylphenyl) pyrrol-2-one inhibitors of cardiac cAMP
phosphodiesterase, J. Med. Chem. 36 (1993) 1041–1047.
[7] C. Grunwald, C. Rundfeldt, H.J. Lankau, T. Arnold, N.
Hofgen, R. Dost, U. Egerland, H.J. Hofmann, K. Unverferth,
Synthesis, pharmacology, and structure-activity relationships of
novel imidazolones and pyrrolones as modulators of GABAA
receptors, J. Med. Chem. 49 (2006) 1855–1866.
[8] R. D´Alessio, A. Bargiotti, O. Carlini, F. Colotta, M. Ferrari, P.
Gnocchi, A. Isetta, N. Mongelli, P. Motta, A. Rossi, M. Rossi, M.
Tibolla, E. Vanotti, Synthesis and immunosuppressive activity of
novel prodigiosin derivatives, J. Med. Chem. 43 (2000) 2557–2565.
[9] M.M. Alam, A. Husain, S.M. Hasan, Suruchi, T. Anwer,
Synthesis and pharmacological evaluation of 2(3H)-furanones
and 2(3H)-pyrrolones, combining analgesic and anti-
inﬂammatory properties with reduced gastrointestinal toxicity
and lipid peroxidation, Eur. J. Med. Chem. 44 (2009) 2636–2642.
[10] S. Olla, F. Manetti, E. Crespan, G. Maga, A. Angelucci, S.
Schenone, M. Bologna, M. Botta, Bioorg. Med. Chem. Lett. 19
(2009) 1512.[11] A. Husain, M.S.Y. Khan, S.M. Hasan, M.M. Alam, 2-Arylidene
4-(4-phenoxyphenyl) but-3-en-4-olides: synthesis, reaction and
biological activity, Eur. J. Med. Chem. 40 (2005) 1394–1404.
[12] A. Husain, M.M. Alam, S.M. Hasan, M.S. Yar, 2(3H)-
furanones and 2(3H)-pyrrolones: synthesis and
antimycobacterial evaluation, Acta Polo. Pharm-Drug Res. 66
(2009) 173–180.
[13] M. Remko, Theoretical study of molecular structure, pKa,
lipophilicity, solubility, absorption, and polar surface area of
some hypoglycemic agents, J. Mol. Struct. (Thoechem) 897
(2009) 73–82.
[14] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney,
Experimental and computational approaches to estimate
solubility and permeability in drug discovery and development
settings, Adv. Drug Deliv. Rev. 23 (1997) 4–25.
[15] www.molinspiration.com
[16] A. Husain, A. Ahmed, V. Ram, A. Bhandari, Synthesis and
antitubercular activity of pyridazinone derivatives, J. Chile.
Chem. Soc. 56 (2011) 778–780.
[17] S. Kanika, Manual of Microbiology Tools and techniques, third
ed., Ane’s Book India, New Delhi, 2007.
[18] R.S. Varma (Ed.), Antifungal Agents: Past, Present and Future
Prospects, National Academy of Chemistry & Biology,
Lucknow, India, 1998.
[19] W.K. Elmer, D.A. Stephen, M.J. William, S.S. Paul, C.W.
Washing, Text Book of Diagnostic Microbiology, ﬁfth ed.,
Lippincot Publishers, 2002.
[20] J.B. Ellen, R.P. Lancer, M.F. Sydney, Bailey and Scott’s
Diagnostic Microbiology, nineth ed., Mosby, 2000.
